Table 1 Summary of median PFS and OS in clinical trials of trabectedin, eribulin, and pazopanib for advanced STS
Agent | Histology | Study type | Year | n | Pre-treatment | PFS (months) | OS (months) | Ref |
|---|---|---|---|---|---|---|---|---|
Trabectedin | L-sarcoma | PhaseIII | 2016 | 345 | 1 or more regimens incl. AI /2 or more regimens incl. anthracyclines | 4.2 | 13.7 | #4 |
Trabectedin | L-sarcoma | PhaseII | 2009 | 136 | 1 or more regimens incl. anthracyclines or ifosfamide | 3.3 | 13.9 | #5 |
Trabectedin | TRS | PhaseII | 2015 | 39 | 0 to 4 regimens | 5.6 | NR | #6 |
Trabectedin | STS | PhaseII | 2005 | 104 | 1 or 2 regimens | 3.5 | 9.2 | #7 |
Trabectedin | STS | Retrospective | 2015 | 885 | - | 4.4 | 12.2 | #8 |
Eribulin | L-sarcoma | PhaseIII | 2016 | 228 | 2 or more regimens incl. anthracyclines | 2.6 | 13.5 | #9 |
Eribulin | STS | PhaseII | 2017 | 51 | 1 or more regimens incl. anthracyclines or ifosfamide | 4.1 | 13.2 | #10 |
Eribulin | Liposarcoma | PhaseII | 2011 | 32 | No more than 1 combination regimen /up to 2 single drug regimens | 2.6 | - | #11 |
Eribulin | Leiomyosarcoma | PhaseII | 2011 | 38 | No more than 1 combination regimen /up to 2 single drug regimens | 2.9 | - | #11 |
Eribulin | Synovial sarcoma | PhaseII | 2011 | 19 | No more than 1 combination regimen /up to 2 single drug regimens | 2.6 | - | #11 |
Eribulin | Others | PhaseII | 2011 | 26 | No more than 1 combination regimen /up to 2 single drug regimens | 2.1 | - | #11 |
Pazopanib | STS excluding liposarcoma | PhaseIII | 2012 | 246 | 1 to 4 regimens incl. anthracyclines | 4.6 | 12.5 | #12 |
Pazopanib | STS | PhaseII | 2009 | 142 | 0 to 2 regimes | 3.0 | 10.6 | #13 |
Pazopanib | Liposarcoma | PhaseII | 2017 | 41 | Any number of regimens | 4.4 | 12.6 | #14 |
Pazopanib | STS | Retrospective | 2016 | 156 | - | 3.6 | 11.2 | #15 |